Innovent Biologics, Inc. announced that the results of two clinical studies of IBI311,a Phase I trial in healthy subjects and a Phase II trial in patients with thyroid eye disease, in the form of oral presentation at the 39th Asia Pacific Academy of Ophthalmology Congress and the 21st International Congress of Endocrinology, respectively.
